Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding Memorandum of Understanding (MOU) with a Vietnam-based pharmaceutical distribution company to explore the development and commercialization of MCS-2 in the Vietnamese pharmaceutical market [1][2]. Group 1: MOU Details - The MOU outlines that both parties will conduct due diligence and discussions to define the scope and structure of any potential collaboration, including commercial strategy, regulatory pathway, and local market execution [2]. - There is no guarantee that a definitive agreement will be reached or that the collaboration will be finalized [2]. Group 2: Strategic Importance - The CEO of Jyong Biotech emphasized that this MOU is a significant step in the company's Asia-focused strategy to introduce plant-derived MCS therapies to new markets, highlighting Vietnam's potential for patient access and local partnerships [3]. - This MOU follows a previously announced non-binding Letter of Intent with a South Korean pharmaceutical company to explore in-licensing and development opportunities for plant-derived MCS products [3]. Group 3: Product Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [4]. Group 4: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with initial market focus on the U.S., EU, and Asia [5]. - Since its establishment in 2002, the company has developed integrated capabilities across all key drug development functions, including early-stage drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [5].

Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding letter of intent with a South Korean pharmaceutical company to explore the potential in-licensing and development of its plant-derived new drug MCS-2 for the Korean market [1][2] Group 1: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][4] - The company has been operational since 2002 and has developed integrated capabilities across drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [4] - Jyong Biotech is advancing several botanical drug candidates, including its primary candidate BOTRESO® and other clinical and preclinical-stage candidates [4] Group 2: Strategic Partnership - The engagement with the South Korean pharmaceutical company aligns with Jyong Biotech's co-commercialization strategy, aiming to leverage the partner's established sales networks and local regulatory expertise [2] - The partnership, if finalized, is expected to enhance market access and patient reach in Korea by utilizing the partner's commercial infrastructure [2][3] - The letter of intent is non-exclusive and subject to due diligence, regulatory review, and negotiation of definitive agreements [2] Group 3: Product Development Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [3] - The company is committed to complying with regulatory disclosure obligations and will provide updates on material developments as they occur [3]

Core Insights - Jyong Biotech Ltd. has achieved a significant milestone in the development of its plant-derived new drug MCS-8 (PCP), focusing on treating urinary system diseases, particularly prostate cancer [1][6] Clinical Trial Results - The Phase II clinical trial of MCS-8 (PCP) involved over 700 high-risk subjects and demonstrated a 27.3% reduction in prostate cancer incidence compared to placebo [2][8] - The trial also showed a 17.1% reduction in the incidence of high-grade prostate cancer (Total Gleason Score ≥ 7) compared to placebo [3][8] - Safety assessments indicated no increase in adverse event rates, with no serious adverse events related to MCS-8 observed [8] Safety and Efficacy - In the MCS-8 group, favorable lipid-modulating trends were observed, including a significant decrease in triglycerides (P = 0.05), a decrease in LDL (P = 0.018), and an increase in HDL (P = 0.003) [4][8] - The placebo group experienced a significant increase in fasting glucose (P = 0.022), while no significant differences were noted in liver function, kidney function, or blood pressure [4][8] Future Development Plans - The company plans to initiate a global Phase III trial in collaboration with international pharmaceutical companies to further validate the clinical potential of MCS-8 [6] - The company has adhered to U.S. FDA guidelines throughout the development process, ensuring rigorous scientific validation and clinical testing [5] Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing innovative plant-derived drugs for urinary system diseases, with initial markets in the U.S., EU, and Asia [1][9] - Since its inception in 2002, the company has built integrated capabilities across drug development, including discovery, clinical trials, regulatory affairs, and commercialization [9]

Group 1 - The top five gainers among Chinese concept stocks include Kuke Music with a rise of 263.64%, Meiyantang with 34.69%, Wangsu Technology with 33.89%, Jian Yong Biotechnology with 24.46%, and Haodingduo with 13.47% [1] - Kuke Music's latest price is 0.0500, with a gain of 0.0363 and a trading volume of 1840.56 thousand [1] - Meiyantang's latest price is 19.140, with a gain of 4.930 and a trading volume of 10.7747 million [1] - Wangsu Technology's latest price is 8.770, with a gain of 2.220 and a trading volume of 2.6759 million [1] - Jian Yong Biotechnology's latest price is 50.020, with a gain of 9.830 and a trading volume of 10.2408 million [1] - Haodingduo's latest price is 3.960, with a gain of 0.470 and a trading volume of 10.7239 million [1]

Group 1 - The top five Chinese concept stocks that experienced the largest declines in closing prices are: Wisdom Logistics down 71.18%, Haodingduo down 34.97%, Jiuzixineng down 20.83%, Jian Yong Biotechnology down 17.76%, and Shangao Life Sciences down 15.97% [1] - Wisdom Logistics (SLGB) closed at 3.000 with a decrease of 41.18%, translating to a drop of 2.100, with a trading volume of 36.8617 million [1] - Haodingduo (MAMK) closed at 3.440, down 34.97%, which is a decrease of 1.850, with a trading volume of 36.2105 million [1] - Jiuzixineng (JZXN) closed at 0.2881, down 20.83%, reflecting a decrease of 0.0758, with a trading volume of 39.3645 million [1] - Jian Yong Biotechnology (MENS) closed at 50.000, down 17.76%, which is a drop of 10.800, with a trading volume of 27.0842 million [1] - Shangao Life Sciences (TATA) closed at 1.000, down 15.97%, translating to a decrease of 0.190, with a trading volume of 613.22 thousand [1]

Core Insights - Jyong Biotech Ltd. has been awarded the Innovation Gold Award for its oral plant-derived investigational new drug BOTRESO® at the 2025 Taipei Biotech Awards, highlighting its commitment to innovation in the biotechnology sector [1][3][4] Company Overview - Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][5] - The company has established integrated capabilities across all key drug development functions, including drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization since its inception in 2002 [5][6] Product Development - BOTRESO® is recognized as the first Taiwan-developed oral botanical new drug to receive U.S. FDA Investigational New Drug (IND) approval and has completed four Phase III clinical trials [2][3] - The product holds multiple invention patents for its pharmaceutical composition globally and has a New Drug Application (NDA) submitted to the U.S. FDA [2][3] Recognition and Future Plans - The award received by the company underscores its leadership in plant-derived drug innovation and its ongoing commitment to delivering effective therapies to patients worldwide [4] - The company aims to expand its global presence and continue developing first-class botanical new drugs to address critical healthcare needs [4]

Core Insights - Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing innovative plant-derived drugs for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][3] - The chairwoman and CEO, Fu Feng Kuo, will speak at The 2025 Global Business Forum, discussing how Taiwan's biotech and medical industries can align with global trends [2][3] Company Overview - Jyong Biotech Ltd. was founded in 2002 and has developed integrated capabilities across all key drug development functions, including drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [3] - The company is advancing several botanical drug candidates, including its primary candidate BOTRESO and other clinical and preclinical candidates [3] Event Details - The Global Business Forum aims to facilitate direct dialogue between U.S. biotech decision-makers and Taiwan's leading drug development enterprises, focusing on strategic themes such as innovative drug technology development, cross-border clinical collaboration, and strategic capital deployment [2][6]

Core Insights - Jyong Biotech Ltd. has completed patient enrollment in its Phase II clinical trial for MCS-8, an investigational drug candidate aimed at prostate cancer prevention, with over 700 high-risk subjects enrolled [1][3] - The trial is randomized and placebo-controlled, taking place across 20 hospitals in Taiwan with the involvement of more than 130 urologists [2] - The company has expressed satisfaction with reaching this milestone, highlighting the team's professionalism and dedication despite challenges posed by the COVID-19 pandemic [3] Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases [4] - Established in 2002, the company has developed integrated capabilities across all key drug development functions, including discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [4] - The company aims to provide first-class innovative drugs to meet health needs and aspires to be a respected organization in the industry [4]

Core Insights - Jyong Biotech Ltd. is a biotechnology company focused on developing plant-derived drugs for urinary system diseases, with a primary emphasis on the U.S., EU, and Asian markets [1][10] Group 1: Clinical Trials and Drug Development - The Phase III clinical trials for BOTRESO included two pivotal studies and two open-label extension studies, with results indicating significant improvement in lower urinary tract symptoms in the Asian subgroup compared to placebo [2] - BOTRESO is the first Taiwanese-developed oral botanical drug to receive IND approval from the U.S. FDA for Phase III trials, showcasing the company's innovative capabilities [4] - MCS-8 (PCP) demonstrated positive results in its Phase II trial, showing lower rates of positive prostate biopsies and high-grade prostate cancer compared to placebo, paving the way for further development [6] Group 2: Market Potential and Growth - The U.S. BPH patient population reached approximately 4.7 million in 2020, reflecting a 6.8% increase since 2017, while the global BPH patient count rose from 88.4 million in 2017 to 94.2 million in 2020 [5] - The global BPH drug market expanded from $3.7 billion in 2017 to $4.1 billion in 2020, with projections indicating it could reach $9.8 billion by 2026, highlighting significant growth potential [5] Group 3: Strategic Partnerships and Global Reach - Jyong Biotech maintains global patent coverage for BOTRESO and has signed multiple letters of intent and licensing agreements with international pharmaceutical partners to support global market entry [8] - The company is in discussions with global pharmaceutical partners for the further development of MCS-8, aiming to initiate large-scale Phase III trials involving thousands of participants [7]

Group 1 - The top five Chinese concept stocks that experienced the largest declines in closing prices are Mint, e家快服, 健永生技, AirNet Technology, and 天演药业, with declines of 33.18%, 21.15%, 18.46%, 17.77%, and 16.59% respectively [1] - Mint's latest price is 5.660, with a drop of 2.810 and a trading volume of 17.6069 million [1] - e家快服's latest price is 1.100, with a decrease of 0.295 and a trading volume of 514.7 thousand [1] - 健永生技's latest price is 40.410, with a decline of 9.150 and a trading volume of 13.7547 million [1] - AirNet Technology's latest price is 2.800, with a drop of 0.605 and a trading volume of 196.45 thousand [1] - 天演药业's latest price is 1.910, with a decrease of 0.380 and a trading volume of 33.98 thousand [1]